Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
2018 · JAMA Oncology · 2,473 citations
https://doi.org/10.1001/jamaoncol.2018.3923
S
Sunandana Chandra
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
165
Papers
7.1K
Citations
29
h-index
54
i10-index
Sunandana Chandra is an academic researcher from Northwestern University. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Melanoma and MAPK Pathways & CAR-T cell therapy research. The author has an h-index of 29, co-authored 141 publications.
ORCID: 0000-0001-7936-5069Papers by this author
worksAcute kidney injury in patients treated with immune checkpoint inhibitors
2021 · Journal for ImmunoTherapy of Cancer · 217 citations
https://doi.org/10.1136/jitc-2021-003467
Sebaceous carcinoma: evidence-based clinical practice guidelines
2019 · The Lancet Oncology · 201 citations
https://doi.org/10.1016/s1470-2045(19)30673-4
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024
2024 · Journal of the National Comprehensive Cancer Network · 100 citations
https://doi.org/10.6004/jnccn.2024.0036
PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
2020 · Nature Communications · 86 citations
https://doi.org/10.1038/s41467-020-19810-w
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
2022 · Journal for ImmunoTherapy of Cancer · 36 citations
https://doi.org/10.1136/jitc-2021-004434
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat